Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are a diverse group of antiretroviral compounds with potent activity against HIV-1 replication. Several are in late stages of clinical development. The antiviral potency, rapid onset of action, and lack of toxicity of NNRTIs will likely make them a useful addition for the practicing clinician treating HIV-infected patients. However, rapid development of viral resistance to NNRTIs will limit the utility of these compounds in monotherapy. Used in combination with other antiretroviral agents, NNRTIs have shown promising results in clinical trials by decreasing viral burden and promoting sustained increases in CD4+T-cell counts. This should lead to an increase in the quality and longevity of life for HIV-infected individuals.

Original languageEnglish (US)
Pages (from-to)715-731
Number of pages17
JournalInfections in Medicine
Issue number8
StatePublished - 1996


  • Acquired immune deficiency syndrome (AIDS)
  • Delavirdine
  • Human immunodeficiency virus (HIV)
  • Nevirapine
  • Non-nucleoside reverse transcriptase inhibitors

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases


Dive into the research topics of 'The new non-nucleoside reverse transcriptase inhibitors'. Together they form a unique fingerprint.

Cite this